Exercise prehabilitation in head and neck cancer patients proposed for definitive chemoradiotherapy: The FIT4TREAT randomized controlled trial.

Oral OncolAug 31, 2026 (epub)
Clinical ResearchOncology (Medical)

Catarina Garcia, Inês Leão, Diogo Pinto et al.

✦ AI-curated · Sources linked

In 30 seconds

The FIT4TREAT randomized controlled trial evaluated the impact of exercise prehabilitation (EP) on functional capacity in patients with head and neck cancer scheduled for definitive chemoradiotherapy. The study found that EP significantly improved the six-minute walk distance (6MWD) by an adjusted difference of 28.6 m compared to usual care, suggesting benefits in physical function and health-related quality of life.

Key findings

  • EP resulted in a significantly greater pre-treatment 6MWD than UC, with an adjusted difference of 28.6 m.
  • EP improved lower-limb functionality with a P-value of <0.001.
  • EP was associated with better preservation in the QLQ-C30 summary score (P=0.008).
  • EP improved social functioning (P=0.038) and body image (P=0.011).

Why it matters

This study highlights the potential of exercise prehabilitation to enhance physical function and quality of life in patients with head and neck cancer prior to chemoradiotherapy, which may inform supportive care strategies in oncology.

Source

PubMed · PMID 42673774

Published in Oral Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.